Wende M. Kozlow

Endocrinology
11505 Rangeland Pkwy
Bradenton, FL 34211

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1 publications

Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo.

Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo.

Journal: Oncotarget
Published: October 20, 2016
Showing 1-1 of 1

Last Updated: 09/26/2026